NCT01421095Active, not recruiting
Ovarian Reserve Testing in Female Young Adult Cancer Survivors
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
Young adult cancer survivors constitute an under served population to whom fertility potential is particularly important. For female young adult patients, cancer treatment such as alkylating chemotherapy are toxic to the finite number of eggs they have, resulting in risks of infertility and premature menopause related to ovarian failure. Reproductive issues are a major concern for young cancer survivors, but one that is understudied. Young cancer survivors have few tools to measure post-treatment ovarian reserve, or the quantity and quality of remaining eggs4. Accurate determination of ovarian reserve and fertility potential would not only be an important research tool, but also directly impact clinical management. The purpose of this study is to test if basal and provocative ovarian reserve testing can predict return of menses in female young adult cancer survivors, to compare basal and provocative ovarian reserve testing results between female young adult cancer survivors and healthy controls, and to compare basal and provocative ovarian reserve testing results between female young adult cancer survivors on and off of combined estrogen and progesterone hormone products. Participants will be asked to keep track of their periods over three months. If a participant is taking birth control pills, patches, or vaginal ring, they will asked to come off the birth control for 3 months. Participants will also be asked to undergo ovarian reserve testing by blood draws and pelvic ultrasounds at the start and end of the 3 months.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- First submitted
- 15 Jun 2011
- Start date
- 1 Jan 2011
- Primary completion date
- Dec 2028
- Lead sponsor
- University of California, San Diego
- Diseases
- Ovarian cancer
- NCT number
- NCT01421095
What you commit to
- Study type: Interventional
- Planned participants: 34
- From 1 Jan 2011 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Estrogen receptor positive cancers
Who the study is looking for
- Postmenarchal
- Cancer diagnosis
- Prior exposure to gonadotoxic therapy, inclusive of chemothearpy, pelvic or total body irradiation, unilateral oophorectomy
- A minimum of 1 year since completion of gonoadotoxic therapy
- Intact uterus
- At least one ovary
Age in the registry: 18 years to 35 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCSD Moores Cancer Center Coordinator of this site? Confirm its status | San Diego | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.